New insider activity at Labcorp Holdings ( (LH) ) has taken place on August 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandra D van der Vaart, the Executive Vice President and Chief Legal Officer of Labcorp Holdings, has recently sold 3,903 shares of the company’s stock. This transaction was valued at an impressive $1,059,352.
Recent Updates on LH stock
Labcorp Holdings has reported strong financial results for Q2 2025, with a 9.5% increase in total revenue to $3.53 billion and a 10.4% rise in adjusted earnings per share to $4.35. The company has raised its full-year guidance, reflecting confidence in its ongoing performance and strategic initiatives. Key factors contributing to this positive outlook include strategic expansions, such as acquisitions and new test introductions in oncology, and robust growth in both the diagnostics and biopharma segments. Despite the positive performance, Labcorp is preparing for potential impacts from PAMA cuts and regulatory uncertainties, which could affect future earnings. The company remains optimistic about its growth trajectory, supported by strategic investments and innovations, while remaining vigilant about potential challenges from regulatory changes and market dynamics.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
Labcorp Holdings achieves a solid overall score, driven by robust earnings performance and positive technical indicators. While the high P/E ratio suggests potential overvaluation, strategic corporate actions and positive earnings guidance underscore future growth potential. However, regulatory risks and margin pressures need to be monitored.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
YTD Price Performance: 18.97%
Average Trading Volume: 717,306
Technical Sentiment Signal: Buy
Current Market Cap: $22.54B